NEWARK, DE — Corrixr Therapeutics appointed oncology drug-development executive Nancy Whiting as board chair as the preclinical genetic-medicine company prepares CXR101 for a regulatory filing and initial human testing in squamous cell cancers.
Whiting succeeds Janice E. Nevin, who will remain on Corrixr’s board after retiring as president and chief executive offic...